Glenmark Life Sciences has announced its financial results for the second quarter of fiscal year 2025, reporting notable declines in both revenue and net profit compared to the same period last year. The company continues to face challenges in maintaining its growth trajectory amidst these declines.
Key Financial Highlights:
- Revenue from Operations:
Glenmark Life Sciences posted revenue of ₹506.88 crore in Q2 FY25, reflecting a 15% drop from ₹595.36 crore in Q2 FY24. Sequentially, revenue also fell from ₹588.62 crore in Q1 FY25, indicating a challenging quarter for the company. - Net Profit:
The company’s net profit for Q2 FY25 stood at ₹95.32 crore, a 20% decrease compared to ₹118.74 crore in Q2 FY24. Additionally, net profit saw a decline from ₹111.48 crore in Q1 FY25, further emphasizing the company’s struggles in profitability.
Half-Year Performance:
For the first half of FY25, Glenmark Life Sciences reported total revenue of ₹1,095.50 crore, down from ₹1,173.81 crore in the same period last year. The net profit for H1 FY25 stood at ₹206.80 crore, compared to ₹254.19 crore in H1 FY24.
While Glenmark Life Sciences is grappling with these financial challenges, the company is expected to focus on improving operational efficiency and expanding its product portfolio to stabilize and enhance its future performance.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. The author or Business Upturn is not liable for any losses arising from the use of this information.
